While a failed ebola drug helped treat hospitalized Covid-19 patients, the common cold virus could become key in treating advanced unresectable cancers. 

San Diego-based Sorrento Therapeutics rejected a non-binding acquisition proposal from a private equity firm, saying that the offer “significantly undervalues Sorrento and is not in the best interest of the company’s stockholders.”

Boehringer Ingelheim exercised an option to buy an EMBL Ventures portfolio company, ViraTherapeutics.

Merck & Co. is driving forward in its quest to develop a premier immuno-oncology pipeline with the acquisition of Australia-based Viralytics Ltd. and its oncolytic immunotherapy treatments.

One year after snagging $41 million in financing, Turnstone Biologics secured additional support through a partnership with Illinois-based AbbVie.

PsiOxus Therapeutics Ltd. agreed to grant Bristol-Myers Squibb Co. exclusive worldwide rights to NG-348, a pre-clinical stage, “armed” oncolytic virus with the goal of addressing solid tumors.